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Cost-utility analyses however require preference based measures
to calculate quality adjusted life years. This study aimed to
estimate the association between health utility and DLQI
response in patients with chronic plaque psoriasis. METHODS:
A consecutive sample of all patients treated for a primary diag-
nosis of psoriasis at Llandough Hospital, Cardiff, UK over a
period of two years were identiﬁed from the hospital record
system. All patients were sent the Health Outcomes Data Reposi-
tory (HODaR) survey including the EQ-5D and DLQI instru-
ments. Individual patient utility was estimated from EQ-5D
responses using the standard UK scoring algorithm. A predictive
regression model was built to estimate EQ-5D utility scores from
patient DLQI responses. RESULTS: A total of 94 psoriasis
patients responded to the survey. Fifty percent of patients were
female, and the mean age was 50.0 years (range from <10 to >80
years). Patients had been diagnosed with psoriasis for a mean of
15.6 years. Over the previous year 20.4% of patients had at least
one inpatient admission and 66.0% at least one outpatient atten-
dance for their psoriasis. Eighteen patients (19%) reported that
they were currently received treatment with a systemic agent or
with PUVA. The regression model found DLQI score to be sig-
niﬁcantly related to the EQ5D utility score. Estimated utility
at zero DLQI, the best possible response, was 0.956 (standard
error 0.039, p < 0.001) and each one point rise in DLQI was
associated with a decrease of 0.02548 (standard error 0.004,
p < 0.001) in estimated utility. The model described 27% of the
variation in the EQ5D data for the survey respondents.
CONCLUSION: It was possible to estimate utility from patient
DLQI score in a population with psoriasis requiring hospital
management.
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OBJECTIVES: To know the repercussion of the moderate-severe
psoriasis on the health-related quality of life (HRQoL), the
health state utilities, the direct costs and the health resources
employees in the last year. METHODS: An observational (natu-
ralistic) study conducted at Dermatology centres in Spain and
Portugal. A total of 332 dermatologists included 10 consecu-
tive patients with moderate to severe psoriasis. The case report
form includes information about the Psoriasis Disability Index
(PDI), as well as variables of severity: Body surface area (BSA)
and Psoriasis Area and Severity Index (PASI). Health state utili-
ties were assessing by the Time Trade-off and Willingness to pay
methods. Data collected also include the direct cost in treatments
and days of sick leave, number of medical visits, hospitalization
days and emergency visits in the last year. RESULTS: 3320
patients were assessed. Mean BSA involvement was 23% (95%
CI: 22.2–23.3%) and mean PASI score was 14.3 (95% CI: 13.9–
14.6%). The mean value of the PDI was 8.93 (IC95% 7.83–
9.21). There was a consistent decrease in HRQoL with increase
in disease severity. The mean amount of remaining life that
patients were willing to sacriﬁce to be free from psoriasis was 25
months (95% CI: 23.4–26.8) and the mean proportion of
monthly income that were willing to pay was 29% (95% CI:
28.1–30.1), with the amount of time or income increasing with
disease severity. In 89% of patients, psoriasis represented a mean
direct treatment expense of 816 € yearly. CONCLUSION: The
psoriasis causes a negative impact in the HRQoL and in the
patient’s budget. This study establish a relationship between
the severity of psoriasis and the amount of money or time of
remaining life that patients are willing to pay or sacriﬁce, respec-
tively, to be free of psoriasis.
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OBJECTIVES: The OSSAS and OSIS are patient reported
outcome measures developed using focus groups to assess facial
Oily Skin (OS) severity and the psychosocial impact of oily skin,
respectively. This study examines the validity and reliability of
these measures in a cross-sectional study. METHODS: The
OSSAS, OSIS and concurrent measures (Skindex and AcneQoL)
were administered to 202 OS patients at seven sites across the
USA. A sub-group of 152 patients returned 1–2 weeks later for
test-retest reliability evaluation. RESULTS: Of the 202 partici-
pants, 72.8% were female; 64.4% had acne in addition to OS.
Item reduction analyses resulted in a 14 item OSSAS with ‘Sen-
sations’ (5 items), ‘Tactile’ (3 items) and ‘Visual’ (4 items)
domains, a single blotting item, and a single overall oiliness item.
The 6 item OSIS includes Annoyance (3 items) and Self-Concept
(3 items) domains. Conﬁrmatory factor analysis provided
support for the construct validity of the ﬁnal item-scale struc-
tures. The OSSAS and OSIS scales had acceptable item conver-
gent validity (item-scale correlations >0.40) and ﬂoor and ceiling
effects (<20%). Cronbach’s alpha coefﬁcients ranged from 0.83–
0.89 for the OSSAS and 0.82–0.87 for the OSIS, demonstrating
excellent internal consistency. The a priori criterion for test-retest
reliability (ICC  0.7) was met for one of the three OSSAS
domains and one of the two OSIS domains. Correlations of the
Skindex-29 and Acne-QoL scales with the OSSAS (range: -0.08–
0.38) and OSIS (range: 0.37–0.73) domain scores met content
expectations for these scales. OSSAS and OSIS domains distin-
guished among groups of patients who differed in terms of both
patient reported facial OS severity (p < 0.0001) and patient
reported bother associated with OS (p < 0.0001). CONCLU-
SION: The OSSAS and OSIS provide valid self-report measures
of facial OS severity and the emotional impact of OS, respec-
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OBJECTIVES: Varenicline (Champix®) is a new drug indicated
for smoking cessation. The objective was to analyse the efﬁciency
of varenicline compared with bupropion, NRT (nicotine replace-
ment therapy) and no pharmacological treatment in Spain.
METHODS: A Markov model was developed to analyse the
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health and economic consequences of smoking cessation thera-
pies. The transition probabilities of morbidity and mortality and
the efﬁcacy were taken from published studies. The model allows
cost effectiveness analyses for different time frames (10 years, 20
years and life time). Outcomes are measured in terms of incre-
mental life years gained (LYG) and QALYs. Pharmacological
costs and costs of medical visits for the treatment with vareni-
cline and bupropion were considered. Treatment costs of
smoking associated morbidity were taken from Spanish studies.
Results were expressed in terms of incremental cost per life year
gained and incremental cost per QALY of varenicline versus
comparators. The analyses were done under the perspective of
the National Health System, discounting costs and health ben-
eﬁts at 3 percent. RESULTS: The life time cost-effectiveness
analysis shows that varenicline dominates all other smoking ces-
sation interventions (more effective at a lower cost). This is due
to the higher efﬁcacy of varenicline associated with a reduction in
smoking related morbimortality, which, in the long term,
accounts for health care cost savings that overcome the extra cost
of varenicline. When shorter timeframes are considered, vareni-
cline presents values under 9.000 €/QALY and 50.000 €/QALY
(analyses at 20 and 10 years respectively). CONCLUSION:
Varenicline is a dominant option (more effective at a lower cost)
compared with all other smoking cessation treatments when the
timeframe is the life span of the patient. Varenicline is cost-
effective even when shorter timeframes are considered (20 years
or more), with an estimated incremental cost per QALY well
bellow the threshold commonly accepted in our environment:
30,000 €/QALY.
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OBJECTIVES: To assess the cost-effectiveness of a structured
community pharmacist based smoking cessation (CPS) program
compared with usual care from health care system perspective in
Thailand. METHODS: A Markov model depicting the conse-
quences of smoking was constructed. Health states included
chronic obstructive pulmonary disease, lung cancer, stroke, coro-
nary heart diseases. Cohorts of 10,000 male and female smokers
with age of 40, 50 and 60 years, who smoke regularly 10–20
cigarettes per day, were simulated until death. Transition prob-
abilities were obtained from literature review, while medical care
costs and utilization patterns were derived from electronic
medical database of a Thai tertiary care hospital and literature.
Costs of a structured community pharmacist based smoking
cessation program were obtained from a costing study of 40 Thai
community pharmacies. Incremental cost per life year gained
(LYG) was calculated. The discount rate used was 3%. A series of
sensitivity analyses including probabilistic sensitivity analyses
were also performed. RESULTS: In base-case analysis, the CPS
program results in cost-savings 17,503.53 baht and gains in life
year of 0.181 year for male; costs-savings 21,499.75 baht and
gains in life years of 0.244 year for female. A series of one-way
sensitivity analyses demonstrate that both cost-savings and gain
in life years were very sensitive to change in discount rate and
long term quit rate of smoking cessation interventions. Based on
probabilistic sensitivity analysis, CPS program led to cost-saving
and life year gained in approximately 84% of the simulation.
CONCLUSION: The CPS program results in cost-saving and
gains in life years compared to usual care. This ﬁnding will be
used as a piece of important information for assisting policy
makers in deciding whether resources should be allocated to
smoking cessation service in community pharmacy.
SMOKING—Patient Reported Outcomes
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OBJECTIVES: Varenicline a a4b2 nicotinic achetylcholine recep-
tor partial agonist has been shown to be effective and cost-
effective as a smoking cessation aid when given as a 12-week
treatment course. Recent data suggests incremental quit rates are
seen if further 12 weeks of varenicline treatment are given. This
study was designed to model the cost-effectiveness of this addi-
tional 12 weeks of varenicline treatment compared with other
available courses of existing smoking cessation drug interven-
tions. METHODS: The authors have previously developed a
Markov model, the Beneﬁts of Smoking Cessation on Outcomes
(BENESCO), which estimates the outcomes and costs of a hypo-
thetical population cohort of current US smokers who make a
single attempt to quit smoking. This is a dynamic micro-
simulation model which models the cost-effectiveness of all the
currently available drug-based smoking-cessation modalities
(NRT/bupropion/varenicline) and unaided cessation. In the origi-
nal version of the BENESCO model, subjects were only allowed
to make a one-off attempt to quit. In this updated version of the
model subjects who have successfully quit following an initial 12
weeks of treatment were permitted a second 12-week treatment
course. Results for maintenance therapy with Varenicline were
encorporated into the BENESCO model using a mixed treatment
comparison. RESULTS: Varenicline, 24 weeks, was found to
dominate bupropion, NRT and unaided smoking cessation strat-
egies over the lifetime of the model. CONCLUSION: Varenicline
when given for 12 or 24 weeks is a highly cost effective smoking
cessation aid. The additional 12 weeks of therapy in initial quit-
ters represents excellent value for money for health services
wishing to reduce the numbers of smokers, smoking-related mor-
bidities and deaths in their populations.
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OBJECTIVES: To evaluate the effects of smoking cessation treat-
ment with varenicline in Germany. METHODS: The health-
economic model follows a hypothetical cohort of smokers in
Germany who make a single attempt to quit smoking. The
Markov model considers the possibility of the following
smoking-related diseases: chronic obstructive pulmonary disease
(COPD), coronary heart disease (CHD), stroke and lung cancer.
The time horizon of the model covers the whole lifespan of the
initial cohort with a discount rate of 5% for costs and health
effects. Smoking cessation with varenicline will be compared
with bupropion, nicotine replacement therapy (NRT) and
unaided cessation (status quo) from the health care system per-
spective. RESULTS: Based on the demographic data used, the
model baseline cohort consists of 5.18 million smokers. On the
basis of the results of this study, smoking cessation with vareni-
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